Palivizumab study for children at high risk of severe RSV
Part of Infections, Lungs & breathing clinical trials.
This study tests a medication called palivizumab to help protect certain children from severe RSV (a common respiratory virus). It is for infants and young children with a higher chance of getting very sick from RSV, such as premature babies or those with certain heart or lung conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is an infant born at or before 35 weeks of pregnancy and is under 6 months old.
- Your child is under 24 months old and has a chronic lung condition (BPD) that required treatment in the last 6 months.
- Your child is under 24 months old and has a significant heart defect (CHD).
- Your child is not currently hospitalized (unless expected to go home within 30 days) or on a breathing machine.
- Your child does not have a current RSV infection or other acute illness with fever in the past week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests a new medicine called SIBP-A16 to help protect infants from RSV, a common virus that can cause serious breathing problems. It is for preterm and full-term infants under 1 year old who are entering their first RSV season.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.